Asset profile
Rimegepant (Nurtec ODT)
Small molecule
Evidence outlook
Approved: Migraine
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
52 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 52 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rimegepant (Nurtec ODT): this drug | Approved | Small molecule | — | ||
| Almotriptan (Axert) | Approved | Small molecule | — | ||
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | — | ||
| Atogepant (Qulipta) | Approved | Small molecule | — | ||
| Celecoxib (Elyxyb) | Approved | Small molecule | — | ||
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | ||
| Dihydroergotamine (Atzumi) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Brekiya) | Approved | — | — | ||
| Dihydroergotamine Mesylate (D.H.E. 45) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Migranal) | Approved | — | — | ||
| Divalproex Sodium (Depakote ER) | Approved | — | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Eletriptan (Relpax) | Approved | Small molecule | — | ||
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | — | ||
| Erenumab (Aimovig) | Approved | Monoclonal antibody | — | ||
| Ergotamine / Caffeine (Cafergot) | Approved | — | — |
…and 37 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
2027 (2)
2028 (7)
January 2028 (1)
June 2028 (1)
August 2028 (1)
What to watch
October 2028 (2)
November 2028 (1)
What to watch
December 2028 (1)
2029 (2)
2030 (1)
July 2030 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.